Disappointing Results For AVI's Eteplirsen

AVI Biopharma Inc.'s (Nasdaq: AVII) muscular dystrophy treatment eteplirsen increased levels of the protein dystrophin but failed to improve walking ability in a midstage clinical trial sending the stock price tumbling 45 cents to $1.09.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.